5-Fluorouracil

Application Notes

5-Fluorouracil (5-FU) inhibits the activity of thymidylate synthetase, which affects pyrimidine synthesis and leads to depletion of intracellular TTP pools. 5-FU has also been proposed to interfere with the activity of ribosomal RNA binding protein (RRBP), at the level of pre-ribosomal RNA (pre-rRNA) processing. 5-Fluorouracil is a potent agent against solid tumors that was introduced in 1957 for clinical use. It remains one of the most effective chemotherapeutic agents in such conditions as colorectal cancer, even at its limited response rates (10 - 30%).

Usage Statement

Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.

Key Applications

Inhibits the activity of thymidylate synthetase

SKU	02101722-CF
Alternate Names	2,4-Dihydroxy-5-fluoropyrimidine; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; 5-FU
Application Notes	5-Fluorouracil (5-FU) inhibits the activity of thymidylate synthetase, which affects pyrimidine synthesis and leads to depletion of intracellular TTP pools. 5-FU has also been proposed to interfere with the activity of ribosomal RNA binding protein (RRBP), at the level of pre-ribosomal RNA (pre-rRNA) processing. 5-Fluorouracil is a potent agent against solid tumors that was introduced in 1957 for clinical use. It remains one of the most effective chemotherapeutic agents in such conditions as colorectal cancer, even at its limited response rates (10 - 30%).
Base Catalog Number	101722
Beilstein Registry Number	127172
Biochemical Physiological Actions	A potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. It is metabolized to ribonucleotides and deoxyribonucleotides, which can be incorporated into RNA and DNA. Treatment of cells with 5-FU leads to an accumulation of cells in S-phase and has been shown to induce p53 dependent apoptosis.
Boiling Point	Decomposes at 282-283 deg C; sublimes (0.1 mm): 190-200 deg C
CAS #	51-21-8
EC Number	200-085-6
Extinction Coefficient	EmM = 7.07 (0.1 M HCl)(Lit.)
Format	Powder
Hazard Statements	H301-H412
Melting Point	Decomposes at 540-541° F (EPA, 1998)
Molecular Formula	C4H3FN2O2
Molecular Weight	130.078 g/mol
pKa	8.0 (Lit.)
Purity	~99%
RTECS Number	YR0350000
Safety Symbol	GHS06
Solubility	less than 1 mg/mL at 66° F (NTP, 1992)
Usage Statement	Unless specified otherwise, MP Biomedical's products are for research or further manufacturing use only, not for direct human use. For more information, please contact our customer service department.
UV Visible Absorbance	λ max: 265 nm (Lit.)
Vapor Pressure	2.68X10-6 mm Hg at 25 deg C (est)